BD BBL Sensi Disc Sulfamethoxazole with Trimethoprim 23.75/1.25 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231536 and 231539®
Published February 14, 2024 · Recall initiated: January 8, 2024
Summary
FDA records medical device Class II recall Z-1039-2024, published February 14, 2024 and initiated January 8, 2024. Recalling firm: Becton Dickinson & Co.; Status: Ongoing; Reported quantity: 2,363,168 total units; Lot: Catalog No. 231536 UDI-DI 00382902315360 Lots 1060689 1116935 1210905 1242939 1306103 1334461 2004540 2025116 2056456 2108378 2146453 2301307 3003869 3062089 3094151 3118079 3152968 3248444 0309595 0343394; Catalog No. 231539® UDI-DI 30382902315392 Lots 2339393 3003869 3062089 3094151 3118079 3152968 3214768 3248444 3282335 0309595 0343394 1060689 1116935 1148543 1210905 1242939 1306103 1334461 2004540 2025116 2056456 2108378 2146453 2277321 2301307. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Becton Dickinson & Co.
- Distributor
- Domestic distribution nationwide. International distribution worldwide.
- Lot
- Catalog No. 231536 UDI-DI 00382902315360 Lots 1060689 1116935 1210905 1242939 1306103 1334461 2004540 2025116 2056456 2108378 2146453 2301307 3003869 3062089 3094151 3118079 3152968 3248444 0309595 0343394; Catalog No. 231539® UDI-DI 30382902315392 Lots 2339393 3003869 3062089 3094151 3118079 3152968 3214768 3248444 3282335 0309595 0343394 1060689 1116935 1148543 1210905 1242939 1306103 1334461 2004540 2025116 2056456 2108378 2146453 2277321 2301307
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDABD Phoenix Panel NMIC-312. Catalog Number: 449082.October 21, 2026
- FDABD Phoenix Panel NMIC-306. Catalog Number: 449292.October 21, 2026
- FDABD GasPak EZ CO2 Pouch System. Catalog Number: 260684. for microbiologic useMay 6, 2026
- FDABD GasPak EZ Campy Pouch System. Catalog Number: 260685. for microbiologic useMay 6, 2026
- FDABD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog NumberFebruary 14, 2024
- FDABD BBL Sensi Disc Tetracycline 30 ug,used for semi-quantitative in vitro susceptibility testing. CatalogFebruary 14, 2024
Questions about this recall
Was BD BBL Sensi Disc Sulfamethoxazole with Trimethoprim 23.75/1.25 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231536 and 231539® recalled?
Yes. FDA published recall Z-1039-2024 on February 14, 2024. Reported hazard: There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
What should I do if I have this product?
Voluntary: Firm initiated · Letter